South Sudan vs Zambia: Average cost of multi drug-resistant tuberculosis treatment
South Sudan
682 constant 2022 US$
in 2024
Zambia
600 constant 2022 US$
in 2024
South Sudan rank
69th
Zambia rank
72nd
Average cost of multi drug-resistant tuberculosis treatment over time
- South Sudan
- Zambia
How they compare
South Sudan currently reports 682 constant 2022 US$ against 600 constant 2022 US$ in Zambia, a difference of 82 constant 2022 US$.
That makes South Sudan's figure about 1.1 times Zambia's.
The two have swapped places 1 time across 6 shared years of data; in 2019 it was Zambia ahead.
South Sudan ranks 69th and Zambia ranks 72nd of 92 countries.
Zambia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | South Sudan | Zambia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,678 constant 2022 US$ | 5,822 constant 2022 US$ | 4,144 constant 2022 US$ | Zambia |
| 2020s | 2,265 constant 2022 US$ | 3,356 constant 2022 US$ | 1,091 constant 2022 US$ | Zambia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, South Sudan or Zambia?
- South Sudan, at 682 constant 2022 US$ against 600 constant 2022 US$ in Zambia as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between South Sudan and Zambia?
- 82 constant 2022 US$, with South Sudan ahead.
- How many years of comparable data are there for South Sudan and Zambia?
- 6 years are reported by both, from 2019 to 2024.
- How do South Sudan and Zambia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- South Sudan ranks 69th and Zambia ranks 72nd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.